Transgenomic to Divest Nucleic Acids Business | GenomeWeb

NEW YORK, Dec. 30 (GenomeWeb News) - Transgenomic's board of directors has voted to "either sell or liquidate" its nucleic acids operating segment, the company said in an SEC filing yesterday.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.